BeStock  
Stocks › Biotechnology › PRME

Prime Medicine PRME

US equityMarket cap rank #3316Biotechnology
$3.55 −$0.29 (-7.55%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $3.56 +0.28%
Open$3.70
Prev close$3.84
Day range$3.49 – $3.94
Volume6.13M
Market cap$791.62M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership87.0%-0.24 pts vs. prior quarter
Institutions holding220-10 vs. prior quarter
Insider trades (recent)40 buys / 10 sellsNet buying
ARK fund activity+1,744,714 sh1 recent transactions · last 10 Nov 2026
Short interest16.07% of floatDays to cover 4.8 · as of 30 Oct 2026
Short-sale volume share21.3%5-day average of daily volume

Short-sale volume as % of daily volume

9%17%25%33%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$4.50M (8 inflow days, 12 outflow days).

Net flow by order size, last 20 sessions

−$1.3MSuper−$3.2MBig−$552.1KMid+$4.3MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 43.1% of shares outstanding.

Largest holders

  • David Liu11.38%
  • Alphabet Inc.9.31%
  • GV Management Company, LLC9.31%
  • Arch Venture Partners, L.P.6.89%
  • Bristol-Myers Squibb Company6.19%
  • BlackRock6.02%
  • ARK Investment Management LLC5.65%
  • State Street Global Advisors3.46%

By investor type

  • Mutual Fund34.79%
  • VC/PE Fund22.15%
  • Public Company18.22%
  • Individual/Insider14.52%
  • Hedge Fund10.31%
  • Private Company0.73%
  • Family Office/Trust0.53%
  • Government Pension Fund0.16%

Reported short interest has fallen from 19.31% to 16.07% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
GWL Investment Management Ltd. Mutual Fund 2026/Q3 +136,523 0.1%
ARK Investment Management LLC Mutual Fund 2026/Q3 +1,694,763 5.6%
BlackRock Mutual Fund 2026/Q3 +1,113,772 6.0%
Amova Asset Management Mutual Fund 2026/Q3 +498,612 1.6%
Sumitomo Mitsui Trust Asset Management Mutual Fund 2026/Q3 +498,612 1.6%
Alessandra Capital Management, LLC Family Office/Trust 2026/Q3 +134,170 0.4%
Russell Investment Management, LLC Mutual Fund 2026/Q3 +124,506 0.1%
Barclays PLC Public Company 2026/Q3 +121,163 0.1%
Pekin Hardy Strauss, Inc. Mutual Fund 2026/Q3 +114,500 0.1%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +245,007 0.1%
ARK Investment Management LLC Mutual Fund 2026/Q3 +2,101,919 4.7%
The Goldman Sachs Group, Inc. Public Company 2026/Q3 +2,029,275 1.3%
Citadel Advisors LLC Hedge Fund 2026/Q3 +1,718,185 1.2%
Leap Investments LP Mutual Fund 2026/Q3 +1,239,598 0.7%
State Street Global Advisors Mutual Fund 2026/Q3 +1,231,335 4.3%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
4 Jun 2026 Robert Taylor Nelsen Independent Director Other Derivative Acquisition +75,000 $3.06 75,000
4 Jun 2026 Michael Kelly Independent Director Other Derivative Acquisition +75,000 $3.06 75,000
4 Jun 2026 Kaye Foster-Cheek Independent Director Other Derivative Acquisition +75,000 $3.06 75,000
4 Jun 2026 David Schenkein Independent Director Other Derivative Acquisition +75,000 $3.06 75,000
4 Jun 2026 Jeffrey Marrazzo Executive Chairperson Other Derivative Acquisition +75,000 $3.06 75,000
4 Jun 2026 Wendy Chung Independent Director Other Derivative Acquisition +75,000 $3.06 75,000
4 Jun 2026 Thomas Cahill Independent Director Other Derivative Acquisition +75,000 $3.06 75,000
25 Feb 2026 Allan Reine Chief Executive Officer Other Derivative Acquisition +1,300,000 $4.38 1,300,000
22 Feb 2026 Ann Lee Chief Technology Officer Other Derivative Acquisition +375,000 $3.34 375,000
22 Feb 2026 Carman Alenson Former Senior VP of Finance & Chief Accounting Officer Other Derivative Acquisition +140,000 $3.34 140,000
31 Jul 2025 Robert Taylor Nelsen Independent Director Derivative Sale to Issuer -84,062 – –
31 Jul 2025 Robert Taylor Nelsen Independent Director Other Derivative Acquisition +84,062 $4.04 45,000
31 Jul 2025 Michael Kelly Independent Director Derivative Sale to Issuer -106,578 – –
31 Jul 2025 Michael Kelly Independent Director Other Derivative Acquisition +106,578 $4.04 45,000
31 Jul 2025 Kaye Foster-Cheek Independent Director Derivative Sale to Issuer -106,578 – –
31 Jul 2025 Kaye Foster-Cheek Independent Director Other Derivative Acquisition +106,578 $4.04 45,000
31 Jul 2025 David Schenkein Independent Director Derivative Sale to Issuer -84,062 – –
31 Jul 2025 David Schenkein Independent Director Other Derivative Acquisition +84,062 $4.04 45,000
31 Jul 2025 Ann Lee Chief Technology Officer Derivative Sale to Issuer -361,990 – –
31 Jul 2025 Ann Lee Chief Technology Officer Other Derivative Acquisition +361,990 $4.04 180,995

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 29,147,049 16.1% 4.8
15 Oct 2026 32,871,532 18.1% 5.5
30 Sep 2026 32,116,376 17.7% 8.5
15 Sep 2026 32,132,218 17.7% 12.3
31 Aug 2026 36,761,940 20.3% 13.1
14 Aug 2026 35,022,290 19.3% 13.8

Discussion

No comments yet — be the first to weigh in on PRME.

Sign in to join the discussion.

Scroll to Top